Redwire SpaceMD to Conduct First Commercial Microgravity Pharmaceutical Mission on SpaceX Starfall Spacecraft in 2028

August 17, 2026

Redwire Corporation / SpaceX USA

Overview

Redwire’s subsidiary, SpaceMD, announced it will execute its first commercial microgravity mission using SpaceX’s new Starfall spacecraft in 2028. This mission will fly 32 Pharmaceutical In-Space Laboratories (PIL-BOXes), significantly expanding in-space manufacturing capabilities for the pharmaceutical and biotechnology sectors. SpaceMD has previously crystallized compounds like insulin in microgravity, and this contract aims to accelerate space-based drug development, promising innovation for terrestrial pharmacology.

In Depth

Key Findings

SpaceMD, a subsidiary of Redwire, has announced its plan to conduct the first commercial microgravity mission utilizing SpaceX’s innovative Starfall spacecraft in 2028. This pioneering mission will deploy 32 Pharmaceutical In-Space Laboratories (PIL-BOXes) to significantly expand in-space manufacturing capabilities within the pharmaceutical and biotechnology sectors. This contract represents a crucial step towards establishing the space environment as a new frontier for drug discovery and development, raising expectations for the production of high-quality crystal structures and materials that are difficult to achieve on Earth.

Technical / Clinical Details

PIL-BOXes are compact, autonomous laboratories designed for the crystallization of pharmaceutical candidate compounds and the manufacturing of biomaterials in microgravity. Through prior ground-based research and past space missions, SpaceMD has successfully crystallized critical compounds such as insulin, demonstrating the beneficial effects of microgravity on crystal growth processes. In microgravity, convection is suppressed, facilitating the growth of more uniform and defect-free crystals. This can lead to enhanced accuracy in structural analysis of drug target proteins, potentially enabling the design of more effective novel drugs. The 32 PIL-BOXes slated for this mission will allow for numerous experiments to run in parallel, expected to accelerate the drug discovery process from lead compound selection to optimization. Additionally, in-space manufacturing is anticipated to contribute to the creation of specialized materials and nanopharmaceuticals that are challenging to synthesize on Earth.

Background & Context

Drug development leveraging microgravity has been researched for years on platforms like the International Space Station (ISS), but the advent of dedicated commercial spacecraft such as SpaceX’s Starfall marks a turning point for the commercialization of this field. Starfall’s capacity for high-volume, low-cost, and frequent payload delivery to orbit provides companies like SpaceMD with opportunities to conduct large-scale microgravity experiments and manufacturing on a commercial basis. The pharmaceutical industry has long grappled with low success rates and high costs in new drug development, drawing attention to microgravity’s potential to resolve these bottlenecks. Redwire is a leader in space infrastructure and on-orbit manufacturing, actively pioneering this new market through SpaceMD. The fusion of commercial space and life sciences is expected to profoundly impact future medicine and materials science.

Strategic Significance & Outlook

The 2028 Starfall mission will serve as a crucial testbed for establishing the commercial viability of space-based pharmaceutical development. If successful, SpaceMD will solidify its position as a pioneer in pharmaceutical manufacturing and biotechnology research in microgravity. In the long term, this could lead to business models akin to ‘space pharmaceutical factories’ that manufacture specific drugs in orbit and supply them to Earth. This prospect could offer a significant competitive advantage, particularly for high-value product segments such as orphan drugs and high-purity materials. Furthermore, this success is expected to catalyze other pharmaceutical and biotechnology companies to enter microgravity R&D, accelerating the growth of the life sciences sector across the entire space industry. The future where space becomes a new hub for drug innovation and advanced manufacturing may soon be upon us.

Source: https://www.facebook.com/RedwireSpace/posts/scaling-the-future-of-pharmaceutical-development-in-space-today-redwires-spacemd/1678967950902475/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.